UPDATE: Living Cell faces slower road to commercialisation as trials get more analysis

(Updates to add share price reaction)
By Rebecca Howard
Nov. 10 (BusinessDesk) - ASX-listed Kiwi biotech firm Living Cell Technologies' shares plunged 84 percent after the company said it won't immediately be seeking provisional consent for its treatment for Parkinson's disease when its latest trial did not show a "statistically significant difference" between people who received the treatment and a control group.
The Melbourne-based company halted trading of its shares yesterday ahead of the trial's results, which it was hoping woul...
Subscribe to BusinessDesk
Stay informed on business, government and financial developments across New Zealand.
- Deeply researched, twice-edited and fact-checked news
- Annual subscribers also receive a complimentary subscription to The Wall Street Journal
- Personalised email news alerts, plus gift up to 5 stories a month to non-subscribers
You can cancel anytime with two clicks, an email or a phone call.
Find out more.
We are serious about journalism.
Already a Subscriber ? Sign in here.
{{ registerForm.errors.get('form') }}
We had trouble validating your card. It's possible your card provider is preventing us from charging the card. Please contact your card provider or customer support.
{{ cardForm.errors.get('card') }}
{{ registerForm.errors.get('plan') }}
{{ __(plans[index].name) | capitalize }}
{{ plans[index].attributes.old_price | currency }}
{{ plans[index].price | currency }}
All subscriptions auto renew but are easy to cancel.
Tax: {{ taxAmount(selectedPlan) | currency }}
Total Price Including Tax: {{ priceWithTax(selectedPlan) | currency }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerSeat ? '/ '+ spark.seatName : '' }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerTeam ? '/ '+ __('teams.team') : '' }} / {{ __(selectedPlan.interval) | capitalize }}
Total Price Including Tax: {{ priceWithTax(selectedPlan) | currency }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerSeat ? '/ '+ spark.seatName : '' }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerTeam ? '/ '+ __('teams.team') : '' }} / {{ __(selectedPlan.interval) | capitalize }}
{{ registerForm.errors.get('email') }}
Not convinced yet?
Subscribe to our free 7am Headlines newsletter.
A quick summary of everything BusinessDesk has published in the previous 24 hours. No BusinessDesk
subscription needed.